Validation of a survival-risk score (SRS) in relapsed/refractory CLL patients treated with idelalisib-rituximab

Blood Cancer J. 2020 Sep 16;10(9):92. doi: 10.1038/s41408-020-00358-3.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't
  • Validation Study

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Antineoplastic Combined Chemotherapy Protocols / administration & dosage*
  • Disease-Free Survival
  • Female
  • Humans
  • Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy*
  • Leukemia, Lymphocytic, Chronic, B-Cell / mortality*
  • Male
  • Middle Aged
  • Purines / administration & dosage
  • Quinazolinones / administration & dosage
  • Rituximab / administration & dosage
  • Survival Rate

Substances

  • Purines
  • Quinazolinones
  • Rituximab
  • idelalisib